"CA46人Burkitt's淋巴瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長(zhǎng)特性：懸浮生長(zhǎng)

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長(zhǎng)速率、鋪板效率、生長(zhǎng)條件和生長(zhǎng)特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長(zhǎng)的快速生長(zhǎng)細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長(zhǎng)期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過(guò)程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長(zhǎng)期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長(zhǎng)。

換液周期：每周2-3次

Granta 519 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HET-1A細(xì)胞、J 774A.1細(xì)胞、Central Adrenergic TH-expressing a細(xì)胞

SHG44 Cells;背景說(shuō)明：SHG-４４細(xì)胞株源自一例２-３級(jí)前沿淋巴結(jié)星細(xì)胞瘤。染色體組型顯示８９.２%的超三倍體。在Wistar大鼠和裸鼠中接種都能成功。細(xì)胞含有神經(jīng)系統(tǒng)特有的S-１００蛋白和星細(xì)胞特有的GFA蛋白;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長(zhǎng)滿。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：HEK293S細(xì)胞、SGC-7901/DDP細(xì)胞、T24(ECV304)細(xì)胞

Anip973 Cells;背景說(shuō)明：肺腺癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：WI-38細(xì)胞、COLO-320-DM細(xì)胞、MDCKII細(xì)胞

CA46人Burkitt's淋巴瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：該細(xì)胞源自Burkitt＇s淋巴瘤患者的B淋巴細(xì)胞，EBNA、Fc陰性。

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

細(xì)胞根據(jù)其形態(tài)和功能可以分為多種類型，其中上皮細(xì)胞、成纖維細(xì)胞和淋巴母細(xì)胞是常見(jiàn)的三種類型。成纖維細(xì)胞，或稱纖維母細(xì)胞，是一種存在于蜂窩組織或纖維結(jié)締組織中的梭形細(xì)胞，能夠分泌構(gòu)成細(xì)胞外基質(zhì)(ECM)的結(jié)構(gòu)蛋白。這類細(xì)胞最初由德國(guó)病理學(xué)家魯?shù)婪颉し茽柦B與法國(guó)解剖學(xué)家馬蒂亞斯·杜瓦爾于19世紀(jì)中葉描述。成纖維細(xì)胞特異性標(biāo)志物包括FAP(成纖維細(xì)胞激活蛋白)、α-SMA(α-平滑肌肌動(dòng)蛋白)、骨膜蛋白、PDGFRα(血小板衍生生長(zhǎng)因子受體α)、膠原蛋白、波形蛋白、纖連蛋白和胸腺細(xì)胞抗原1等。成纖維細(xì)胞在形態(tài)上是扁平的紡錘形細(xì)胞，缺乏基底膜，細(xì)胞核呈圓形拉長(zhǎng)，被巨大的內(nèi)質(zhì)網(wǎng)包圍。在培養(yǎng)中，它們表現(xiàn)出不同的形態(tài)學(xué)和生化特征，這取決于其起源位置、分化狀態(tài)和培養(yǎng)條件。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來(lái)源說(shuō)明：細(xì)胞主要來(lái)源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫(kù)

CA46人Burkitt's淋巴瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來(lái)源：人源、鼠源等其它物種來(lái)源

Mouse Bladder Tumor line-2 Cells;背景說(shuō)明：膀胱移行細(xì)胞癌；C３H/He;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NPA87-1細(xì)胞、Porcine Kidney-15細(xì)胞、IPLB-SF-21細(xì)胞

KMST6 Cells;背景說(shuō)明：胚成纖維細(xì)胞；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MH7A細(xì)胞、SUM102PT細(xì)胞、NB19-RIKEN細(xì)胞

C57 Mouse Tumor 93 Cells;背景說(shuō)明：結(jié)腸癌；C５７BL/ICRF;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Ramos(RA1)細(xì)胞、HeLa-229細(xì)胞、Sf21細(xì)胞

BT 549 Cells;背景說(shuō)明：該細(xì)胞１９７８年由W.G.Coutinho和E.Y.Lasfargues建系，源自一位７２歲患有乳腺導(dǎo)管癌的白人女性，來(lái)源組織包括乳頭及浸潤(rùn)導(dǎo)管。該細(xì)胞形態(tài)包括上皮樣細(xì)胞及多核巨細(xì)胞，可分泌一種粘性物質(zhì)。;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：DU4475細(xì)胞、HS-729細(xì)胞、Mouse podocyte細(xì)胞

┈訂┈購(gòu)(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號(hào)】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：淋巴母細(xì)胞樣

正確的細(xì)胞復(fù)蘇需知事項(xiàng)：細(xì)胞凍存HAO了，接下來(lái)要注意什么問(wèn)題呢？沒(méi)錯(cuò)，就是記得到時(shí)間了，拿出來(lái)復(fù)蘇。那么，細(xì)胞復(fù)蘇的過(guò)程中又有哪些該注意的事項(xiàng)呢？細(xì)胞活力和形態(tài)檢查的作用何在？活力檢查——千萬(wàn)不要使用不健康的細(xì)胞，可能有污染(真菌、支原體等)，如果發(fā)現(xiàn)有污染毫不猶豫的丟棄!形態(tài)檢查——檢查細(xì)胞的固有形態(tài)和生長(zhǎng)行為。凍存細(xì)胞：補(bǔ)充新的培養(yǎng)——在您開(kāi)始凍存細(xì)胞的前一天補(bǔ)充新的培養(yǎng)。在細(xì)胞長(zhǎng)至７０%單層時(shí)收獲細(xì)胞，計(jì)數(shù)活細(xì)胞數(shù)，用凍存調(diào)整細(xì)胞密度~５ x１０６  s/ml (根據(jù)不同的細(xì)胞類型調(diào)整)；凍存——用凍存洗細(xì)胞并用凍存重懸細(xì)胞，有不同類型的凍存，根據(jù)細(xì)胞類型選擇Zui合適的凍存(常用的凍存成分有)：５-１０% DMSO——注意確保DMSO不含有其他的毒性物質(zhì)；５-１５%甘油；如果細(xì)胞在無(wú)血清培養(yǎng)基內(nèi)生長(zhǎng)，應(yīng)在５０%條件培養(yǎng)基內(nèi)(細(xì)胞在無(wú)血清培養(yǎng)基內(nèi)生長(zhǎng)２４小時(shí))內(nèi)凍存和復(fù)蘇。在凍存管上標(biāo)記HAO細(xì)胞類型，日期，凍存人等信息，并保證每?jī)龃婀懿怀^(guò)１.５ml。放入罐之前記錄凍存管的數(shù)量和位置。以Zui快的速度轉(zhuǎn)移凍存管知罐內(nèi)，因此，此步驟ZuiHAO使用干冰，或者把凍存管浸入裝有的小盒內(nèi)。此外還要注意，在凍存管上沒(méi)有足夠的空間記錄細(xì)胞的詳細(xì)信息，做HAO記錄是非常非常重要的！還有一個(gè)Zui重要的，一定要在異地的罐內(nèi)保存同樣的一份細(xì)胞，以免其中的一個(gè)罐出現(xiàn)問(wèn)題！細(xì)胞正確的復(fù)蘇方式和正確的凍存方式同樣重要，熟記以下要點(diǎn)：當(dāng)從罐內(nèi)取出細(xì)胞時(shí)，有可能會(huì)出現(xiàn)凍存管破裂的情況，使用保護(hù)面罩和防護(hù)服十分必要；其實(shí)，細(xì)胞復(fù)蘇只是一個(gè)簡(jiǎn)單的實(shí)驗(yàn)，不過(guò)這其中卻不可避免有一些需要注意的細(xì)節(jié)，不然，也不一定會(huì)盡如人意。例如說(shuō)，人身健康方面：一定要記得做HAO防凍工作，戴上護(hù)目鏡；盡量降低DMSO對(duì)細(xì)胞的損傷等等。

HEK-EBNA Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１０傳代；每周２次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SK-ES細(xì)胞、Statens Seruminstitut Rabbit Cornea細(xì)胞、MD Anderson-Metastatic Breast-436細(xì)胞

UPCISCC090 Cells;背景說(shuō)明：舌鱗癌細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LA-4 [Mouse lung adenoma]細(xì)胞、2PK-3細(xì)胞、3T3F442A細(xì)胞

OCI-AML-2 Cells;背景說(shuō)明：急性髓系白血病；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PSN1細(xì)胞、DMS79細(xì)胞、KLE細(xì)胞

UMC-11 Cells;背景說(shuō)明：肺腫瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Human Embryo Kidney-2細(xì)胞、TSCCa細(xì)胞、SNU-620細(xì)胞

SP-2 Cells;背景說(shuō)明：該細(xì)胞是由綿羊紅細(xì)胞免疫的BALB/c小鼠脾細(xì)胞和P３X６３Ag８骨髓瘤細(xì)胞融合得到的。該細(xì)胞不分泌免疫球蛋白，對(duì)２０μg/ml的８-氮鳥(niǎo)嘌呤有抗性，對(duì)HAT比較敏感；該細(xì)胞可以作為細(xì)胞融合時(shí)的B細(xì)胞組分用于制備雜交瘤；鼠痘病毒陰性。;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞樣；圓形;相關(guān)產(chǎn)品有：FBHE細(xì)胞、U-226AR1細(xì)胞、BNL 1ME A.7R.1細(xì)胞

MM6 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：Kit225細(xì)胞、Rabbit Kidney 13細(xì)胞、C3A細(xì)胞

FRH-0201 Cells;背景說(shuō)明：膽管癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：LNCaP-Clone-FGC細(xì)胞、H-125細(xì)胞、SCLC-21H細(xì)胞

RFL 6 Cells;背景說(shuō)明：胚肺；成纖維細(xì)胞；SD大鼠;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BT 325細(xì)胞、HEC1-A細(xì)胞、SUM52細(xì)胞

L-M[TK-] Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：FRTL 5細(xì)胞、H2286細(xì)胞、C57 Mouse Tumor 93細(xì)胞

CCC-HHM-2 Cells;背景說(shuō)明：心肌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CL40細(xì)胞、NCIH2171細(xì)胞、CCD19-Lu細(xì)胞

P30 OHK Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１０^５ cells/６０mm dish;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：Ly1細(xì)胞、M-1細(xì)胞、SK-MEL-31細(xì)胞

KYSE 70 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：REC細(xì)胞、Pt-K1細(xì)胞、Kit225-K6細(xì)胞

RAW2647 Cells;背景說(shuō)明：?jiǎn)魏司奘杉?xì)胞白血?。恍坌?；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：P30/OHK細(xì)胞、0V-1063細(xì)胞、SNU520細(xì)胞

OCI AML5 Cells;背景說(shuō)明：急性髓系白血病細(xì)胞；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-1693細(xì)胞、Hs-688A-T細(xì)胞、X63Ag8.653細(xì)胞

NCI-H1944 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２—３次;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RBL2H3細(xì)胞、RA細(xì)胞、NCI-H596細(xì)胞

MDAMB134 Cells;背景說(shuō)明：該細(xì)胞１９７３年由R. Cailleau建系，源自７４歲乳腺導(dǎo)管癌女性患者的胸腔積液，細(xì)胞生長(zhǎng)緩慢，松散貼壁，生長(zhǎng)過(guò)程中會(huì)脫落到培養(yǎng)基，不會(huì)匯合，過(guò)表達(dá)FGF受體;傳代方法：１：２—１：４傳代，每周換液２—３次;生長(zhǎng)特性：松散貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：HIT.T15細(xì)胞、Panc-10.05細(xì)胞、Nittby-Salford 1細(xì)胞

HLEpiC Cells;背景說(shuō)明：晶狀體；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Tca8113細(xì)胞、AAV293細(xì)胞、DHL5細(xì)胞

Abcam HEK293T HNRNPUL1 KO Cells(提供STR鑒定圖譜)

AG10760 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line PST118 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XC874 Cells(提供STR鑒定圖譜)

bTS5 Cells(提供STR鑒定圖譜)

CpHi41 Cells(提供STR鑒定圖譜)

DA04171 Cells(提供STR鑒定圖譜)

DA06214 Cells(提供STR鑒定圖譜)

GM00751 Cells(提供STR鑒定圖譜)

WEHI-279 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：P31FUJ細(xì)胞、LICCF細(xì)胞、PC14細(xì)胞

CA46人Burkitt's淋巴瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

P36 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?，?３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：MGSMC細(xì)胞、NCIH2227細(xì)胞、NHDF細(xì)胞

NT2-D1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Lewis Lung細(xì)胞、SK-MES細(xì)胞、A253細(xì)胞

PIGI Cells;背景說(shuō)明：皮膚；黑色素細(xì)胞；HPV１６轉(zhuǎn)化；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：GTL 16細(xì)胞、HS-683細(xì)胞、Y3細(xì)胞

NCIH889 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：每周換液２-３次;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：LS180細(xì)胞、SK-HEP-1細(xì)胞、FHL 124細(xì)胞

PSN1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：６傳代，２-３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SVEC4-10細(xì)胞、TOV21G細(xì)胞、DiFi細(xì)胞

2G10 [Mouse hybridoma against human TYR] Cells(提供STR鑒定圖譜)

VMCUB1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-508細(xì)胞、CEMC1細(xì)胞、PANC0403細(xì)胞

Opossum Kidney Cells;背景說(shuō)明：腎;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SK RC 52細(xì)胞、Stanford University-Diffuse Histiocytic Lymphoma-1細(xì)胞、NHA細(xì)胞

H841 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：５傳代，;生長(zhǎng)特性：混合型生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：B16 F1細(xì)胞、MonoMac1細(xì)胞、TE-671細(xì)胞

NCI-H2228 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代，每周２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEM細(xì)胞、CaES-17細(xì)胞、Jiyoye(P-2003)細(xì)胞

HEK-293A Cells;背景說(shuō)明：胚腎；腺病毒包裝;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：ECV-304細(xì)胞、U-373 MG細(xì)胞、KPL-4細(xì)胞

SK Mel28 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８?jìng)鞔?，?３天換液１次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：星形的;相關(guān)產(chǎn)品有：USMC細(xì)胞、KU 812F細(xì)胞、RWPE-2細(xì)胞

NCIH2029 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：５傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：16-HBE細(xì)胞、CFPAC1細(xì)胞、Transformed Human Liver Epithelial-3細(xì)胞

Psi2 DAP Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH128細(xì)胞、A9(Hamprecht)細(xì)胞、ML2細(xì)胞

GM22439 Cells(提供STR鑒定圖譜)

HAP1 MFN2 (-) 2 Cells(提供STR鑒定圖譜)

SKGT2 Cells;背景說(shuō)明：胃底癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs 895 T細(xì)胞、SK LU 1細(xì)胞、TE 32細(xì)胞

MiaPaCa2 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代；;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEC151細(xì)胞、CA 46細(xì)胞、KM12SM細(xì)胞

H-2107 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng) ;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：rUCMSCs細(xì)胞、HDQP1細(xì)胞、H-1688細(xì)胞

SCL-2 Cells;背景說(shuō)明：皮膚鱗癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BNCL-2細(xì)胞、LNCaP subline C4-2細(xì)胞、PIG3細(xì)胞

NCI-HUT-520 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：P3J HR-1細(xì)胞、RS(4;11)細(xì)胞、MF2059細(xì)胞

TE-12 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SKNBE細(xì)胞、U2-OS細(xì)胞、SuDHL 1細(xì)胞

GCT0404 Cells;背景說(shuō)明：骨巨細(xì)胞瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HS766T細(xì)胞、Roswell Park Memorial Institute 1788細(xì)胞、SL1細(xì)胞

Ra No. 1 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：Hs 852.T細(xì)胞、Li-7細(xì)胞、TCC-SUP細(xì)胞

HPSI1114i-kuul_2 Cells(提供STR鑒定圖譜)

KCB 200547L Cells(提供STR鑒定圖譜)

MG-63/MTXR8 Cells(提供STR鑒定圖譜)

NIMHi002-A Cells(提供STR鑒定圖譜)

RAW 264.7 Lrrk2 KO + HALO-human LRRK2 LIR1+LIR2 mutant + HA-human GABARAP Cells(提供STR鑒定圖譜)

Ubigene HEK293 RIPK3 KO Cells(提供STR鑒定圖譜)

WIBR3_DJ1_X1-5DEL_Het_2046 Cells(提供STR鑒定圖譜)

HEK-Blue mTLR7 Cells(提供STR鑒定圖譜)

BNL 1MEA.7R.1 Cells;背景說(shuō)明：肝；上皮細(xì)胞；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CHO K1細(xì)胞、SF17細(xì)胞、NCTC 1469細(xì)胞

Panc-3_27 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：WiDr細(xì)胞、SUIT 2細(xì)胞、PC3M-2B4細(xì)胞

C-26 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-SNU-878細(xì)胞、NS-1-Ag4-1細(xì)胞、J-774A.1細(xì)胞

ETCC-007 Cells;背景說(shuō)明：原位導(dǎo)管癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HEL-92-1-7細(xì)胞、UT-7細(xì)胞、HCC1187細(xì)胞

UM-UC-3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：16HBEo-細(xì)胞、A704細(xì)胞、AN3CA細(xì)胞

UM-UC-3 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：16HBEo-細(xì)胞、A704細(xì)胞、AN3CA細(xì)胞

SK-N-BE(2)C Cells;背景說(shuō)明：神經(jīng)母細(xì)胞瘤；骨髓轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：MDA-MB157細(xì)胞、NCI-H64細(xì)胞、J-111細(xì)胞

HELF Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長(zhǎng)特性：貼壁生長(zhǎng)　;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BAR-T細(xì)胞、MBT-2細(xì)胞、CAL-120細(xì)胞

TR146 Cells;背景說(shuō)明：食管鱗癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NK-92 transfected with MFG-hIL2細(xì)胞、T98 G細(xì)胞、TF-1細(xì)胞

Hs 832(C).T Cells;背景說(shuō)明：卵巢，惡性囊腫;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H-2085細(xì)胞、NW38細(xì)胞、HCC-202細(xì)胞

UM-UC14 Cells;背景說(shuō)明：腎癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCIH510細(xì)胞、OVCAR 8細(xì)胞、Psi2-DAP細(xì)胞

UPCISCC154 Cells;背景說(shuō)明：舌鱗癌；男性；HPV６轉(zhuǎn)化;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：FTC133細(xì)胞、SK-N-BE(1)n細(xì)胞、138 MG細(xì)胞

D-324 Med Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：多邊形;相關(guān)產(chǎn)品有：NCI-SNU-182細(xì)胞、HCT-116細(xì)胞、H2066細(xì)胞

NCIH2171 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：３-４天換液１次。;生長(zhǎng)特性：懸浮生長(zhǎng);形態(tài)特性：聚團(tuán)懸浮;相關(guān)產(chǎn)品有：CAL-148細(xì)胞、NCI-H2073細(xì)胞、LICR-LON-HN6細(xì)胞

NR-8383 Cells;背景說(shuō)明：NR８３８３(正常大鼠，１９８３年８月３日)來(lái)源于肺灌洗時(shí)的正常大鼠肺泡巨噬細(xì)胞。細(xì)胞在gerbil肺細(xì)胞連續(xù)培養(yǎng)液存在下培養(yǎng)了大約８-９個(gè)月。隨后，不再需要外源生長(zhǎng)因子。通過(guò)有限稀釋法從單個(gè)細(xì)胞克隆并亞克隆NR８３８３細(xì)胞，并三次用軟瓊脂亞克隆。細(xì)胞表現(xiàn)出巨噬細(xì)胞的特性，吞噬酵母多糖和銅綠，非特異性脂酶活性，F(xiàn)c受體，氧化降解；分泌IL-１,TNFbeta和IL-６，可重復(fù)地響應(yīng)外源生長(zhǎng)因子。NR８３８３細(xì)胞響應(yīng)博萊霉素，分泌TGFbeta前體。在博萊霉素刺激下，TGFbe;傳代方法：１：２傳代;生長(zhǎng)特性：半貼壁生長(zhǎng);形態(tài)特性：巨噬細(xì)胞;相關(guān)產(chǎn)品有：SU4細(xì)胞、NK92細(xì)胞、HFL 1細(xì)胞

STAN106i-121C1 Cells(提供STR鑒定圖譜)

FHs74Int Cells;背景說(shuō)明：小腸;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：D341細(xì)胞、KP-N-RT-BM細(xì)胞、CAL85-1細(xì)胞

SR786 Cells;背景說(shuō)明：間變性大細(xì)胞淋巴瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NOR-10細(xì)胞、NCIH1944細(xì)胞、639-V細(xì)胞

LTEP-a-2 Cells;背景說(shuō)明：肺腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：BOWES細(xì)胞、SKNBE(2c)細(xì)胞、A498細(xì)胞

Pro-5WgaRI3C Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-SNU-423細(xì)胞、NCIH69細(xì)胞、Hs 934.T細(xì)胞

H2122 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：４傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁生長(zhǎng);形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：HTR-8/SV-neo細(xì)胞、H2023細(xì)胞、RMa-bm細(xì)胞

Hx-147 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：PLB 985細(xì)胞、MES-23.5細(xì)胞、PG-4細(xì)胞

CA46人Burkitt's淋巴瘤細(xì)胞代次低|培養(yǎng)基|送STR圖譜

C8161 Cells;背景說(shuō)明：皮膚黑色素瘤；腹壁轉(zhuǎn)移；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：H1238細(xì)胞、H196細(xì)胞、FO [Mouse myeloma]細(xì)胞

HCT.116 Cells;背景說(shuō)明：結(jié)腸腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：SO-Rb 50細(xì)胞、P3-X63-Ag8-653細(xì)胞、SHSY-5Y細(xì)胞

WIL2S Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：TGW細(xì)胞、HOC細(xì)胞、SF-539細(xì)胞

NS-20Y Cells;背景說(shuō)明：神經(jīng)母細(xì)胞瘤；雄性；A/J;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：CCRF CEM細(xì)胞、A549細(xì)胞、Bx-PC3細(xì)胞

FRTL5 Cells;背景說(shuō)明：甲狀腺；自發(fā)永生；Fischer;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HPASMC細(xì)胞、RDES細(xì)胞、ARO細(xì)胞

WEHI 3 Cells;背景說(shuō)明：白血?。籅ALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：懸浮;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：NCI-H292細(xì)胞、COLO-357細(xì)胞、BHT-101細(xì)胞

MALME 3M Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：４傳代，２天換液１次。;生長(zhǎng)特性：混合生長(zhǎng);形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：Hs-940細(xì)胞、S16細(xì)胞、BRL-3A細(xì)胞

BLO-11 Cells;背景說(shuō)明：詳見(jiàn)相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長(zhǎng)特性：貼壁或懸浮，詳見(jiàn)產(chǎn)品說(shuō)明書(shū)部分;形態(tài)特性：詳見(jiàn)產(chǎn)品說(shuō)明書(shū);相關(guān)產(chǎn)品有：HIT T15細(xì)胞、JB 6細(xì)胞、SK HEP 01細(xì)胞

BayGenomics ES cell line RRB102 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line XE393 Cells(提供STR鑒定圖譜)

CW39-1B10 Cells(提供STR鑒定圖譜)

MH94 Cells(提供STR鑒定圖譜)

Sq-1979 233-1 Cells(提供STR鑒定圖譜)

LS180-SLC27A3-KO-c6 Cells(提供STR鑒定圖譜)

" "PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336

Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.

Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.

J. Immunol. 129:1336-1342(1982)

PubMed=3921823; DOI=10.1128/mcb.5.3.501-509.1985; PMCID=PMC366742

Showe L.C., Ballantine M., Nishikura K., Erikson J., Kaji H., Croce C.M.

Cloning and sequencing of a c-myc oncogene in a Burkitt's lymphoma cell line that is translocated to a germ line alpha switch region.

Mol. Cell. Biol. 5:501-509(1985)

PubMed=3080238

Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.

Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.

Cancer Res. 46:1182-1188(1986)

PubMed=3100061; DOI=10.1016/0008-8749(86)90099-7

Benjamin D., Bazar L.S., Wallace B., Jacobson R.J.

Heterogeneity of B-cell growth factor receptor reactivity in healthy donors and in patients with chronic lymphatic leukemia: relationship to B-cell-derived lymphokines.

Cell. Immunol. 103:394-408(1986)

PubMed=3026973; DOI=10.1002/ijc.2910390215

Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.

Expression of B-cell-specific markers in different Burkitt lymphoma subgroups.

Int. J. Cancer 39:211-218(1987)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883

Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.

p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=1325212; DOI=10.1182/blood.V80.5.1289.1289

Benjamin D., Knobloch T.J., Dayton M.A.

Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

Blood 80:1289-1298(1992)

PubMed=8220424; DOI=10.1038/ng0993-56

Bhatia K.G., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.T.

Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.

Nat. Genet. 5:56-61(1993)

PubMed=8316623; DOI=10.2307/3578190

Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J., Olive P.L.

DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.

Radiat. Res. 134:307-315(1993)

PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493

Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.

Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.

FASEB J. 7:951-956(1993)

PubMed=8402660

O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.

Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.

Cancer Res. 53:4776-4780(1993)

PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418

Jain V.K., Judde J.-G., Max E.E., Magrath I.T.

Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.

J. Immunol. 150:5418-5428(1993)

PubMed=8176200; DOI=10.4049/jimmunol.152.10.4749

Benjamin D., Sharma V., Knobloch T.J., Armitage R.J., Dayton M.A., Goodwin R.G.

B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors.

J. Immunol. 152:4749-4757(1994)

PubMed=8558920

Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.

The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.

Leukemia 10:142-149(1996)

PubMed=8568269; DOI=10.4049/jimmunol.156.4.1626

Benjamin D., Sharma V., Kubin M., Klein J.L., Sartori A., Holliday J., Trinchieri G.

IL-12 expression in AIDS-related lymphoma B cell lines.

J. Immunol. 156:1626-1637(1996)

PubMed=9192833

Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S., Pike S.E., Gupta G., Magrath I.T., Tosato G.

Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells.

Cancer Res. 57:2508-2515(1997)

PubMed=9473234; DOI=10.1182/blood.V91.5.1680

Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.

p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.

Blood 91:1680-1687(1998)

PubMed=9643977; DOI=10.1016/S0378-1119(98)00104-8

Khaira P., James C.D., Leffak M.

Amplification of the translocated c-myc genes in three Burkitt lymphoma cell lines.

Gene 211:101-108(1998)

PubMed=9787181; DOI=10.1182/blood.V92.9.3410

Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.

PTEN gene alterations in lymphoid neoplasms.

Blood 92:3410-3415(1998)

PubMed=9973220

Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G., Magrath I.T., Bhatia K.G.

Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.

Cancer Res. 59:696-703(1999)

PubMed=10567774; DOI=10.1159/000007237

Fan S.-J., Duba D.E., O'Connor P.M.

Cellular effects of olomoucine in human lymphoma cells differing in p53 function.

Chemotherapy 45:437-445(1999)

PubMed=11587216; DOI=10.1038/sj.leu.2402281

Zimonjic D.B., Keck-Waggoner C.L., Popescu N.C.

Novel genomic imbalances and chromosome translocations involving c-myc gene in Burkitt's lymphoma.

Leukemia 15:1582-1588(2001)

PubMed=12145705; DOI=10.1038/sj.leu.2402519

Langerak A.W., Moreau E.J., van Gastel-Mol E.J., van der Burg M., van Dongen J.J.M.

Detection of clonal EBV episomes in lymphoproliferations as a diagnostic tool.

Leukemia 16:1572-1573(2002)

PubMed=16960149; DOI=10.1182/blood-2006-06-026500

Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R., Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M., Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F., Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S., Martinez-Climent J.A.

Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Blood 109:271-280(2007)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x

Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K., Hasegawa H., Yamada Y.

Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations.

Eur. J. Haematol. 82:301-307(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22885699; DOI=10.1038/nature11378; PMCID=PMC3609867

Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L., Wright G., Shaffer A.L. 3rd, Hodson D.J., Buras E., Liu X.-L., Powell J.I., Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.M., Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.-C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Nature 490:116-120(2012)

PubMed=24590883; DOI=10.1002/gcc.22161

Murga Penas E.-M., Schilling G., Behrmann P., Klokow M., Vettorazzi E., Bokemeyer C., Dierlamm J.

Comprehensive cytogenetic and molecular cytogenetic analysis of 44 Burkitt lymphoma cell lines: secondary chromosomal changes characterization, karyotypic evolution, and comparison with primary samples.

Genes Chromosomes Cancer 53:497-515(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145

Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.

High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.

J. Virol. 89:713-729(2015)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940.1-940.13(2018)

PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

Screening human cell lines for viral infections applying RNA-Seq data analysis.

PLoS ONE 14:E0210404-E0210404(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)"